Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin He
A phase 3 trial of AZD0486 in chronic lymphocytic leukaemia, run by AstraZeneca, now recruiting.
Overview
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV) is a phase 3 interventional study registered as NCT07509151 by AstraZeneca, with 420 participants planned, started 2026-05-05 and due to reach its primary completion in 2031-08-29. Interventions recorded: Surovatamig. Conditions listed: Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
Shares AZD0486, AstraZeneca.
- TrialA Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Shares AZD0486, AstraZeneca.
- TrialSurovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Shares AZD0486, AstraZeneca.
- TrialACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Shares Chronic lymphocytic leukaemia, AstraZeneca.
- TrialA Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Shares Chronic lymphocytic leukaemia, AstraZeneca.
- TrialA Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Shares AZD0486, Chronic lymphocytic leukaemia, AstraZeneca.
- TrialStudy of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
Shares Chronic lymphocytic leukaemia, AstraZeneca.
- TrialA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Shares Chronic lymphocytic leukaemia, AstraZeneca.